Angiogenic factors and the risk of preeclampsia: A systematic review and meta-analysis

Yousef Veisani1 Ph.D., Ensiyeh Jenabi2 Ph.D., Ali Delpisheh3 Ph.D., Salman Khazaei4 Ph.D.

1Psychosocial Injuries Research Center, Ilam University of Medical Sciences, Ilam, Iran.
2Pediatric Developmental Disorders Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.
3Department of Clinical Epidemiology, Ilam University of Medical Sciences, Ilam, Iran.
4Research Center for Health Sciences, Hamadan University of Medical Sciences, Hamadan, Iran.

Abstract

Background: The etiological nature of preeclampsia is heterogeneous. The use of biomarkers indices in early pregnancy helps to have appropriate stratification of pregnancies into high- and low risk for the purpose of choosing timely interventions.

Objective: The aim of this systematic review was to determine the pathogenic role of soluble soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) in the prediction of preeclampsia in women.

Materials and Methods: We performed a systematic search of the international databases including PubMed, Scopus, and Web of Science until August 2017. The quality of included studies was assessed using the Newcastle-Ottawa Scale. The primary outcome in this review was preeclampsia. The statistical heterogeneity was assessed using the X² test and quantified by I². Pooled effects size was obtained by random effects model. Subgroup analyses were also carried out.

Results: Totally, 284 records were identified in the initial search and 15 records were finally included in the meta-analysis. The pooled odds ratios (ORs) for the association between the high level of sFlt-1 and low level of PlGF and subsequent development of preeclampsia among women were 5.20 (95% CI: 1.24–9.16) and 2.53 (95% CI: 1.33–3.75), respectively. The mean difference for sFlt-1 and PlGF in women with preeclampsia compared to controls was 1.15 (95% CI: 0.43–1.86) and –0.94 (95% CI: –1.37–0.52), respectively.

Conclusion: According to the results from this meta-analysis, increased levels of sFlt-1 and reduced levels of PlGF predict the subsequent development of preeclampsia.

Key words: Angiogenic factors, Preeclampsia, sFLT-1, PlGF.
1. Introduction

Preeclampsia is a multiorgan disease process characterized by hypertension and proteinuria. The severe preeclampsia happens with epigastric pain, headache, impaired vision, impaired liver function, thrombocytopenia, kidney dysfunction, red blood cell breakdown and low blood platelet count (1, 2). Preeclampsia is associated with maternal and fetal adverse outcomes, and occurs in 2–8% of pregnancies. It is responsible for up to 15% of preterm births (3). Some risk factors may play a main role in the etiology of preeclampsia. These risk factors include diabetes mellitus, obesity, overweight, maternal age, nulliparity, high blood pressure, hypothyroidism, renal disease and family history of preeclampsia (4). The etiology for the pathogenesis of preeclampsia is yet to be fully known (5). Some studies proposed that placenta releases soluble angiogenic factors, which play a crucial role in endothelial dysfunction and development of preeclampsia-related symptoms before clinical manifestation of preeclampsia. The soluble fms-like tyrosine kinase-1 (sFlt-1) is one of these factors. It binds vascular endothelial growth factor (VEGF) A and placental growth factor (PIGF). They are the angiogenic main factors that are responsible for placental vascular development and function of mother endothelial (6). Different studies have shown that the rate of the two factors is more precise for diagnosing and prediction of preeclampsia than any of the factors alone. There is little data on sFlt1 or PIGF in pregnant women with major preeclampsia risk factors, and the majority have a small sample size. Too small a sample usually prevents the findings from being extrapolated, and significance relations may not be seen, however, the diagnose of preeclampsia based on the cut-off values of these two factors is still unknown and the results are inconsistent (6, 7).

To the best of our knowledge, no meta-analysis has been carried out regarding the effect of angiogenic factors on the risk of preeclampsia. Therefore, this meta-analysis was conducted for assessing the association between the angiogenic factors and the risk of preeclampsia.

2. Materials and Methods

2.1. Data sources

We performed a comprehensive systematic manual and electronic search to assess the pathogenic role of soluble sFlt-1 and PIGF in the prediction of preeclampsia. The PRISMA statement (8) was used to report this study (Figure 1). The relevant studies were systematically searched in international databases including Pub Med, Scopus, and Web of Science from database inception until August 2017.

2.2. Search strategy

The search strategy was performed by the medical subject headings (MeSH) in the title, keywords, and abstracts (risks; factor; angiogenically; risk of; angiogen; pre-eclampsia; factors; angiogenicity; preeclampsia; risk; angiogenic, s-Flt-1, PLGF, biochemical blood marker; and Pregnancy) and were combined with Boolean Operators: AND and OR. After removing the duplicate articles, relevancies were checked by title and abstract review. Finally, to ensure the relevance of screened articles, their full text was reviewed. The cross-referencing publication was done in order to increase the sensitivity of the initial search. There was no restriction applied on language and publication year. Among 284 selected articles in the initial search, 88 duplicate articles were removed; 159 articles rejected after reviewing abstracts, and 22 final articles remained for full-text evaluation, after these process 15 full-papers were finally selected for meta-analysis.
2.3. Inclusion and exclusion criteria

Original researches (Case-controls and cohorts) which include these terms of examining both angiogenic factors in women with preeclampsia with two groups design, reporting of outcome information, also articles that reported the serum levels of sFlt-1 (pg per millilitre) and Free PlGF (pg per millilitre) were considered as inclusion criteria. Articles lacking reporting of the gestational age of participants and duplicate articles as well as animal studies were excluded also case reports, case series, comments, editorials, and reports were considered as exclusion criteria.

The outcome definitions were as described in the definition of PE from the International Society for the study of Hypertension in Pregnancy (9). Two investigators (S.K., E.J.) independently reviewed the full-text of articles to assess their eligibility in the meta-analysis. Any disagreement between the two was resolved by discussion within the team of authors.

2.4. Data extraction

After review of all searched articles (title, abstract, and full text), irrelevant studies were excluded from the study. For the studies that were eligible for meta-analysis, the following information was extracted: publication year, first author, study population, trimester of pregnancy, total sFlt-1 (pg per milliliter), Free PlGF (pg per milliliter), number of subjects in each group, standard deviation, odds ratio (OR), their associated 95% confidence intervals (CI), and study design.

2.5. Quality assessment

Newcastle-Ottawa Scale (NOS) was used for quality assessment of the studies (10). The abstracting instrument included 8 items and 11 scores possible. Eventually, articles were classified to high quality (scoring ≥5 points) or low quality (scoring < 5 points). In this meta-analysis, all the articles that obtained five or more points were included.

2.6. Statistical analysis

The current meta-analysis was applied by two effect sizes (Mean Difference (MD) and Odds Ratio (OR)). The association of preeclampsia and angiogenic factors was reported by pooled OR. In addition, we used the MD to compare the serum level of angiogenic factors between women with preeclampsia and control group. The statistical heterogeneity among the results of included studies was investigated by X2 and quantified using I^2. In this study, the random effects model was used when the heterogeneity was moderate to high (I^2 > 25). Begg and Egger’s tests were used to assess publication bias in included studies (11). All meta-analysis and meta-regressions were performed using Stata software version 12 (Stata Corp, College Station, TX, USA). For all effect estimates, a value of p < 0.05 was considered to be statistically significant.

3. Results

Figure 1 shows the results of the literature review and selection process. A total of 284 potentially relevant articles were identified from the initial literature review (221 for major international databases and 63 for hand searching and reference lists of the identified articles). After removing the duplicates, 196 articles remained, and then the authors excluded 159 articles by screening the titles and abstracts. After full-text examination 22 articles were excluded due to improper study design or missing data. Finally, 15 studies met the eligibility criteria for meta-analysis.

Full characteristics of included studies are shown in table I. From 15 included studies, 14 studies had case-control design and one was a cohort study. All studies are published in English.
The risk of preeclampsia in women with high level of sFlt-1 was reported in three articles (12, 18, 20). The OR of the risk of subsequent development of preeclampsia in women with levels higher than the cutoff value of sFlt-1 was 5.20 (95% CI: 1.24–9.16), which means that sFlt-1 increases 5.2 times the risk of preeclampsia in cases groups. The results of $I^2$ statistic showed a positive heterogeneity in articles ($I^2 = 81.7\%$; $p \leq 0.004$) (Figure 2).

The risk of preeclampsia in women with low level of PlGF was reported in four articles (12, 14, 17, 18). The OR of the risk of subsequent development of preeclampsia in women with levels lower than the cut-off value of PlGF was 2.53 (95% CI: 1.33–3.75), which means that PlGF increases 2.53 times the risk of preeclampsia in cases groups. The results of $I^2$ statistic did not show heterogeneity ($I^2 = 0.0\%$; $p \leq 0.80$) (Figure 3).

Mean of sFlt-1 in 14 studies was reported. The MD was significantly increased in intervention group 1.15 (95% CI: 0.43–1.86), which concluded higher level of sFlt-1 in women with preeclampsia. The results of $I^2$ statistic showed a positive heterogeneity in articles ($I^2 = 97.9\%$; $p \leq 0.001$) (Figure 4).

The mean of PlGF was reported in 15 studies. The MD was significantly decreased in preeclampsia group –0.94 (95% CI: –1.37–0.52), which concluded lower level of PlGF in women with preeclampsia. The results of $I^2$ statistic showed a positive heterogeneity in articles ($I^2 = 94.6\%$; $p \leq 0.001$) (Figure 5).

In this meta-analysis, patients with preeclampsia were classified as preterm (<37 wk) or term ($\geq 37$ wk), according to the gestational age at which preeclampsia was diagnosed in enrolled studies. According to the subgroup analysis, the MD of sFlt-1 was significantly increased in intervention group 1.71 (95% CI: 0.63–2.72); therefore, patients with a higher positive change in sFlt-1 had a higher risk for the development of preterm preeclampsia. Also, patients with a low change in PlGF –1.01 (95% CI: –1.46–0.56) had a higher risk for the development of preterm preeclampsia (Table II).

The possibility of publication bias was explored by Beggs test, but our results were not indicated of publication bias ($Z: –0.84; p = 0.400$). Therefore, we tried considering the most of published articles in this subject (Figure 6).

### Table I: The characteristic of included studies.

| Author (ref no) | Year | Country | Design | Women with Preeclampsia | Controls | Assessed factors | Gestational age | Quality |
|----------------|------|---------|--------|-------------------------|----------|------------------|----------------|---------|
| Levine et al. (12) | 2004 | USA | C-C | 120 | 120 | sFlt-1, PlGF | $\geq 37$ Wk | High |
| Polliotti et al. (13) | 2003 | USA | C-C | 20 | 60 | sFlt-1, PlGF | $< 34$ Wk | High |
| Shibata et al. (14) | 2005 | USA | C-C | 26 | 27 | sFlt-1, PlGF | 34–35 Wk | High |
| Wells et al. (10) | 2016 | Brazil | C-C | 40 | 20 | sFlt-1, PlGF | 37–40 Wk | High |
| Tsatsaris et al. (15) | 2003 | Belgium | C-C | 29 | 31 | sFlt-1, PlGF | 30–372 Wk | High |
| Woodham et al. (16) | 2011 | USA | C-C | 41 | 123 | sFlt-1, PlGF | $\geq 37$ Wk | High |
| Erez et al. (17) | 2008 | USA | C-C | 39 | 201 | sFlt-1, PlGF | $\geq 37$ Wk | High |
| Kusanovic et al. (18) | 2009 | USA | C | 32 | 1560 | sFlt-1, PlGF | $< 37$ Wk | High |
| Thadhani et al. (19) | 2004 | USA | C-C | 40 | 80 | sFlt-1, PlGF | 1–12 Wk | High |
| Lim et al. (20) | 2008 | Korea | C-C | 40 | 100 | sFlt-1, PlGF | $\geq 37$ Wk | High |
| Haggerty et al. (21) | 2012 | Denmark | C-C | 211 | 213 | sFlt-1, PlGF | $< 27$ Wk | High |
| Crispi et al. (22) | 2008 | Spain | C-C | 36 | 76 | sFlt-1, PlGF | $< 32$ Wk | High |
| March et al. (23) | 2015 | Spain | C-C | 24 | 35 | sFlt-1, PlGF | $> 34$ Wk | High |
| De Vivo et al. (24) | 2008 | Italy | C-C | 52 | 52 | sFlt-1, PlGF | $\geq 37$ Wk | High |
| Sunderji et al. (25) | 2010 | USA | C-C | 48 | 409 | sFlt-1, PlGF | 20–36 Wk | High |

Note: C-C: case-control; C: cohort; sFlt-1: Soluble fms-like tyrosine kinase-1; PlGF: Placental growth factor.
Table II: Changes in the angiogenic factors (sFlt-1 and PlGF) between the preterm (< 37 weeks) or term (≥ 37 weeks) of preeclampsia.

| Angiogenic factors | MD (95% CI) | Heterogeneity |
|--------------------|-------------|---------------|
|                    |             | I²  | p-value |
| sFlt-1             |             |     |         |
| < 37 Wk of gestation | 1.71 (0.63, 2.72) | 98.3 | < 0001 |
| ≥ 37 Wk of gestation | 0.44 (–0.60, 1.48) | 97.7 | < 0001 |
| PlGF               |             |     |         |
| < 37 Wk of gestation | –1.01 (–1.46, –0.56) | 91.6 | < 0001 |
| ≥ 37 Wk of gestation | –0.85 (–1.73, 0.03) | 96.8 | < 0001 |

Note: MD: The mean difference; sFlt-1: Soluble fms-like tyrosine kinase 1; PlGF: Placental growth factor.

Records identified through database searching: Pubmed (46), ISI (22), Scopus (28), Iran Medex (29), Magiran (25), SID (42), and Medlib (29) (n=221)

Additional records identified through other sources (n= 63)

Records after duplicates removed (n= 196)

Records screened (n= 196)

Records excluded (n= 159)

Full-text articles assessed for eligibility (n= 37)

Full-text articles excluded, with reasons (n= 22)

Studies included in qualitative synthesis (n= 15)

Studies included in quantitative synthesis (meta-analysis) (n= 15)

Figure 1: The flow diagram of selected articles in meta-analysis.
**Figure 2:** The results of meta-analysis in regard to the risk of subsequent development of preeclampsia in women with a higher value of sFlt-1 than cut-off point. The effect size is OR. Diamonds represent the overall pooled estimates of the risk of preeclampsia.

**Figure 3:** The results of meta-analysis in regard to the risk of subsequent development of preeclampsia in women with a lower value of PlGF than the cut-off point. The effect size is OR. Diamonds represent the overall pooled estimates of the risk of preeclampsia.
Figure 4: The MD for sFlt-1 in women with preeclampsia compared to controls. The effect size is MD. Diamonds represent overall pooled estimates of effects of higher sFlt-1 on preeclampsia.

Figure 5: The MD for PlGF in women with preeclampsia compared to controls. The effect size is MD. Diamonds represent overall pooled estimates of effects of lower PlGF on preeclampsia.
4. Discussion

This meta-analysis was conducted for the assessment of pathogenic roles of sFlt-1 and PlGF to predict the risk of preeclampsia in women. According to our knowledge, this is the first meta-analysis that assessed the association between angiogenic factors and preeclampsia, by best available evidence. In this meta-analysis, for careful attention, NOS tool was used for quality assessment. The abnormalities of numerous angiogenic factors are in relation with preeclampsia, but sFlt-1 and the PlGF were most studied.

According to our results, increased levels of sFlt-1 predict the risk of preeclampsia in women. Also, reduced levels of PlGF had a significant role in preeclampsia in women. Therefore, an angiogenic imbalance in pregnant woman significantly related to preeclampsia. These findings are consistent with the results of previous reports that reported increasing concentrations of sFlt-1 increased the risk of preeclampsia in women (26, 27), which occurred about five weeks before the incident of preeclampsia. The decreasing level of free PI GF and free VEGF that take place at the time of increase level of sFlt-1 to some extent may be attributable in part to the binding by sFlt-1. According to our findings, the MD of sFlt-1 was significantly increased in women with preeclampsia compared to the control groups; this rate is about 15%. Also, the MD of PI GF was significantly decreased in preeclampsia. Previous articles have reported that the decrease in the PI GF level beginning early in the second trimester is the main predictor for preeclampsia (19, 28). Haggerty et al. showed that low concentrations of PI GF during early gestation have a much greater risk of early-onset preeclampsia (21). Levine et al. showed that angiogenic imbalance is significantly to be greater in women who had early onset preeclampsia and also in pregnant women who delivered a small-for-gestational-age infant, the best explanations are defective angiogenesis in these cases (12).
According to our findings, patients with a higher positive change in sFlt-1 and also patients with a low change in PIGF had a higher risk for the development of preterm preeclampsia. On the other hand, first- to second-trimester changes in angiogenic biomarkers are predictive of preterm preeclampsia.

Currently, there is no widely accepted screening test for the prediction of preeclampsia in pregnant women. However, according to our findings, angiogenic factors can be considered as a screening tool for preeclampsia. Help in decision-making as well as the better decision in resource allocation are some other applications of our results.

There are some limitations in this meta-analysis. Firstly, due to the different inclusion and/or exclusion criteria, the heterogeneity between the studies was high; therefore, the analysis of the source of heterogeneity was limited due to different sources. Secondly, articles that were reported effects size (OR) were limited, therefore final pooled analysis was limited to four articles. Thirdly, the design of all studies was retrospective cohort and mainly case-control study, therefore results were more prone to selection bias, and information on exposure is subject to observation bias in case-control studies. Finally, data that were provided by the studies included in the meta-analysis were not sufficient to perform some subgroup analyses based on confounding variables like gestational age and other clinical subgroups.

5. Conclusion

In summary, our results show that the sFlt-1 concentration is five times higher in a woman with preeclampsia compared to the control groups, accompanied by a decrement in the circulating free PIGF levels. Therefore, our findings supported the results of previous reports regarding the important biologic role of angiogenic factors in preeclampsia.

Acknowledgments

The authors declare that they did not receive any funding for this study.

Conflict of Interest

The authors declare that they have no conflict of interest.

References

[1] Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration (BMI Mediated Effects), Lu Y, Hajifathalian K, Ezzati M, Woodward M, Rimm EB, et al. Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1·8 million participants. Lancet 2014; 383: 970–983.

[2] American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American college of obstetricians and gynecologists’ task force on hypertension in pregnancy. Obstet Gynecol 2013; 122: 1122–1131.

[3] Kim SY, Ryu HM, Yang JH, Kim MY, Han JY, Kim JO, et al. Increased sFlt-1 to PIGF ratio in women who subsequently develop preeclampsia. J Korean Med Sci 2007; 22: 873–877.

[4] Poorolajal J, Jenabi E. The association between body mass index and preeclampsia: a meta-analysis. J Matern Fetal Neonatal Med 2016; 29: 3670–3676.

[5] Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 2011; 123: 2856–2869.

[6] Tarasevičienė V, Grybauskienė R, Mačiulevičienė R. sFlt-1, PIGF, sFlt-1/PIGF ratio and uterine artery Doppler for preeclampsia diagnostics. Medicina (Kaunas) 2016; 52: 349–353.

[7] Verlohren S, Gailindo A, Schlembach D, Zeisler H, Herraz I, Moertl MG, et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010; 202: 161. e1–161.e11.
[8] Peters JP, Hooft L, Groiman W, Stegeman I. Reporting quality of systematic reviews and meta-analyses of otorhinolaryngologic articles based on the PRISMA statement. PLoS One 2015; 10: e0136540–e0136550.

[9] Tranquill AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertens 2014; 4: 97–104.

[10] Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2009 Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

[11] Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629–634.

[12] Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672–683.

[13] Polliotti BM, Fry AG, Sailer DN, Mooney RA, Cox C, Miller RK. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol 2003; 101: 1266–1274.

[14] Shibata E, Rajakumar A, Powers RW, Larkin RW, Gilmour C, Bodnar LM, et al. Soluble fms-Like Tyrosine Kinase 1 Is Increased in Preeclampsia But Not in Normotensive Pregnancies with Small-for-Gestational-Age Neonates: Relation to Circulating Placental Growth Factor. J Clin Endocrinol Metab 2005; 90: 4895–4903.

[15] Tsatsaris V, Goffin F, Munaut C, Brichant JF, Pignon MR, Noel A, et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 2003; 88: 5555–5563.

[16] Woodham PC, Brittain JE, Baker AM, Long DL, Haeri S, Camargo CA, et al. Midgestation maternal serum 25-hydroxyvitamin D level and soluble fms-like tyrosine kinase 1/placental growth factor ratio as predictors of severe preeclampsia. Hypertension 2011; 58: 1120–1125.

[17] Erez O, Romero R, Espinoza J, Fu W, Todem D, Kusunovic JP, et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 2008; 21: 279–287.

[18] Kusunovic JP, Romero R, Chaiworapongs T, Erez O, Mittal P, Vaisbuch E, et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Maternal Fetal Neonatal Med 2009; 22: 1021–1038.

[19] Thadhani R, Mutter WP, Wolf M, Levine RJ, Taylor RN, Sukhatme VP, et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004; 89: 770–775.

[20] Lim JH, Kim SY, Park SY, Yang JH, Kim MY, Ryu HM. Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors. Obstet Gynecol 2008; 111: 1403–1409.

[21] Haggerty CL, Seifert ME, Tang G, Olsen J, Bass DC, Karumanchi SA, et al. Second trimester anti-angiogenic proteins and preeclampsia. Pregnancy Hypertens 2012; 2: 158–163.

[22] Crisp F, Llurba E, Domínguez C, Martín-Gallán P, Cabero L, Gratacos E. Predictive value of angiogenic factors and uterine artery Doppler for early-versus late-onset pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol 2008; 31: 303–309.

[23] March MI, Geachhan C, Wenger J, Raghruman N, Berg A, Haddow H, et al. Circulating angiogenic factors and the risk of adverse outcomes among haitian women with preeclampsia. PloS One 2015; 10: e0126815.

[24] De Vivo A, Baviere G, Giordano D, Todarello G, Corrado F, D’Anna R. Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand 2008; 87: 837–842.

[25] Sunderji S, Gaziano E, Wothe D, Rogers LC, Sibai B, Karumanchi SA, et al. Automated assays for sVEGF R1 and PI GF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. Am J Obstet Gynecol 2010; 202: 40.e1–7.

[26] Maynard SE, Min JY, Merchant J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649–658.

[27] Koga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, Hirata T, et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 2003; 88: 2348–2351.

[28] Taylor RN, Grimwood J, Taylor RS, McMaster MT, Fisher SJ, North RA. Longitudinal serum concentrations of placental growth factor: Evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 188: 177–182.